Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PYGL | P06737 | 5/20 | 0.46 |
| ▸ | PYGM | P11217 | 5/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | IL1RN | P18510 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13904707 | 1.00 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL29415830 | 1.00 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1269652 | 1.00 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1270022 | 1.00 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL25379502 | 0.98 | ANPEP (0.53) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL1975348 | 0.98 | ANPEP (0.53) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9405630 | 0.90 | MAPT (0.54) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL24859077 | 0.90 | MAPT (0.54) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| Trifluoroacetic Acid SCHEMBL29675191 | 0.87 | PYGL (0.44) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| Pidolic Acid SCHEMBL1270175 | 0.83 | SMYD3 (0.44) | NPC1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| CN-110835319-B | Synthesis method of benazepril intermediate and benazepril hydrochloride | 杭州馨佳源环保科技有限公司 | 2023-06-20 | — | — | CN | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-5843941-A | Ras farnesyl transferase inhibitors | GENENTECH, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0763537-A2 | Non-peptidyl Ras farnesyl transferase inhibitors | GENENTECH, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0513974-B1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO INC (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5532359-A | FUNGICIDES | GENENTECH, INC. (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0698015-A1 | PREPARATION OF N-CYANODITHIOIMINO-CARBONATES AND 3-MERCAPTO-5-AMINO-1H-1,2,4-TRIAZOLE | GENENTECH, INC. (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026723-A2 | ras FARNESYL TRANSFERASE INHIBITORS | GENENTECH, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| US-5310737-A | Benzo-fused lactams that promote the release of growth hormone | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5206235-A | Animal growth regulators; stimulants | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0513974-A1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | NPC1 4591/4885MAPK13 38/4885MAPK12 101/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | NPC1 1136/4885MAPK13 316/4885MAPK12 375/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | NPC1 1287/4885MAPK13 288/4885MAPK12 364/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | NPC1 1287/4885MAPK13 288/4885MAPK12 364/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | NPC1 1287/4885MAPK13 288/4885MAPK12 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.